DEVELOPMENT FUNDING BOND PURCHASE AGREEMENTDevelopment Funding Bond Purchase Agreement • March 16th, 2022 • MorphoSys AG • Pharmaceutical preparations • New York
Contract Type FiledMarch 16th, 2022 Company Industry JurisdictionThis DEVELOPMENT FUNDING BOND PURCHASE AGREEMENT, dated as of June 2, 2021 (this “Agreement”), is made and entered into by and between MorphoSys AG, a German stock corporation (Aktiengesellschaft) (the “Guarantor”), and Royalty Pharma USA, Inc., a Delaware corporation (the “Buyer”), and, effective as of its execution of a Joinder at or following the closing of the Merger (as defined below), Constellation Pharmaceuticals, Inc., a Delaware corporation (the “Issuer”).
Royalty Purchase Agreement By and Between MorphoSys AG and Royalty Pharma Investments 2019 ICAV Dated as of June 2, 2021Royalty Purchase Agreement • March 16th, 2022 • MorphoSys AG • Pharmaceutical preparations • New York
Contract Type FiledMarch 16th, 2022 Company Industry Jurisdiction
Purchase and Sale Agreement By and Between MorphoSys AG andPurchase and Sale Agreement • March 16th, 2022 • MorphoSys AG • Pharmaceutical preparations • New York
Contract Type FiledMarch 16th, 2022 Company Industry JurisdictionThis REVENUE AND PARTICIPATION RIGHTS PURCHASE AND SALE AGREEMENT, dated as of June [_], 2021 (this “Agreement”), is made and entered into by and between Royalty Pharma Investments 2019 ICAV, an Irish collective-asset management vehicle (the “Buyer”), and MorphoSys AG, a German public limited company (the “Company”).